ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33,
Keywords: مگامولیزومب; Brentuximab vedotin; Daratumumab; Gemtuzumab ozogamicin; Infection; Inotuzumab ozogamicin; Lucatumumab; Mogamulizumab; Moxetumomab pasudotox;